Rinaldi L, Lisi F, Selman H
RISEL-One Day Medical Center, Via Attilio Ambrosini 114, 00147, Rome, Italy,
J Endocrinol Invest. 2014 Jan;37(1):65-70. doi: 10.1007/s40618-013-0021-1. Epub 2014 Jan 8.
Recently, an increased scientific interest was focused on mild approaches for ovarian stimulation in clinical practice. Milder stimulation aims to develop safer and more patient-friendly protocols which are more physiological, less drug use, less expensive and the risks of treatment are highly minimized.
To investigate the efficacy and safety of a mild ovarian stimulation protocol in patients at high risk of developing ovarian hyperstimulation syndrome (OHSS), compared to conventional long down-regulation protocol.
This a prospective, open, randomized study, included 349 infertile patients considered at high risk of developing OHSS, undergoing in vitro fertilization treatment in two private assisted reproduction centers. The patients were randomized into two groups: group A (n = 148) had a mild/minimal stimulation protocol of recombinant FSH (rFSH) combined with GnRH antagonist. Group B (n = 201) (control group) had a standard long protocol of rFSH combined with GnRH agonist.
There was no significant difference observed between the two groups regarding the mean number of oocytes retrieved per patient, mature metaphase II oocytes, fertilization rate, and embryo cleavage rate. Significantly higher implantation rate (21.5 vs 14.5 %) (p < 0.05), pregnancy rate (37.7 vs 23.4 %) (p < 0.05), and delivery rate (32.8 vs 20.1 %) (p < 0.05) were observed in favor of groups A compared to group B. Lower proportion of patients (4.7 %), though not statistically significant, has developed OHSS in group A compared to group B (8.4 %).
Our study shows that mild stimulation regimen is highly effective for ovarian stimulation of patients who have experienced OHSS complication without increasing the risk of OHSS.
最近,临床实践中对温和的卵巢刺激方法的科学兴趣有所增加。温和刺激旨在开发更安全、更有利于患者的方案,这些方案更符合生理、药物使用更少、成本更低,且治疗风险高度最小化。
与传统的长效降调节方案相比,研究温和卵巢刺激方案在发生卵巢过度刺激综合征(OHSS)高危患者中的疗效和安全性。
这是一项前瞻性、开放性、随机研究,纳入了349例被认为有发生OHSS高危的不孕患者,在两家私立辅助生殖中心接受体外受精治疗。患者被随机分为两组:A组(n = 148)采用重组促卵泡激素(rFSH)联合GnRH拮抗剂的温和/最小刺激方案。B组(n = 201)(对照组)采用rFSH联合GnRH激动剂的标准长效方案。
两组在每位患者回收的平均卵母细胞数、成熟的中期II卵母细胞、受精率和胚胎分裂率方面未观察到显著差异。与B组相比,A组的着床率(21.5%对14.5%)(p < 0.05)、妊娠率(37.7%对23.4%)(p < 0.05)和分娩率(32.8%对20.1%)(p < 0.05)显著更高。A组发生OHSS的患者比例(4.7%)低于B组(8.4%),尽管无统计学意义。
我们的研究表明,温和刺激方案对曾经历OHSS并发症的患者进行卵巢刺激非常有效,且不会增加OHSS风险。